{"analyses":[{"ciNumSides":"TWO_SIDED","groupDescription":"Estrogen receptor (ER) or progesterone receptor (PR) positive correlation with progression-free survival for patients on study treatment.","groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Hazard Ratio (HR)","paramValue":"-0.564","statisticalMethod":"Cox Proportional Hazards","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33"}]}],"title":"ER or PR Positive"},{"categories":[{"measurements":[{"groupId":"OG000","value":"14"}]}],"title":"ER and PR Negative"}],"denoms":[{"counts":[{"groupId":"OG000","value":"47"}],"units":"Participants"}],"groups":[{"id":"OG000","title":"Women Treated With Adjuvant Regimen for High Risk Uterine LMS"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"2 years","title":"Correlation Between Estrogen Receptor (ER) or Progesterone Receptor (PR) Positive and Tumor Response to Treatment (PFS)","type":"SECONDARY","unitOfMeasure":"participants"}